Condition: Idiopathic Pulmonary Fibrosis · Sponsor: Pliant Therapeutics, Inc.
A randomized, double-blind, dose-ranging, placebo-controlled study to evaluate the efficacy and safety of bexotegrast (PLN-74809) for the treatment of idiopathic pulmonary fibrosis (BEACON-IPF).
This description comes directly from the study's public registry record.
Contact details are listed per location below or on the registry record.
Always discuss trial participation with your own doctor first.
| University of Alabama at Birmingham | Birmingham, Alabama, United States | — |
| Arizona Pulmonary Specialists | Phoenix, Arizona, United States | — |
| Dignity Health-St. Josephs Hospital and Medical Center | Phoenix, Arizona, United States | — |
| Banner University Medical Center | Tucson, Arizona, United States | — |
| Cedars Sinai Medical Center | Los Angeles, California, United States | — |
| Newport Native MD, Inc | Newport Beach, California, United States | — |
| Palmtree Clinical Research | Palm Springs, California, United States | — |
| VA Palo Alto Health Care System | Palo Alto, California, United States | — |
| Paradigm Clinical Research Institute Inc - ClinEdge | Redding, California, United States | — |
| University of California Davis Comprehensive Cancer Center | Sacramento, California, United States | — |
| UCSF Medical Center - Pulmonary Practice | San Francisco, California, United States | — |
| Jeffrey S. Sager, MD Medical Corporation | Santa Barbara, California, United States | — |
+ 256 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06097260